Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 4/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.48 |
| ▸ | HTR3B | O95264 | 3/20 | 0.48 |
| ▸ | HTR3A | P46098 | 3/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR5A | P47898 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15517942 | 0.88 | LTA4H (0.44) | LTA4HHTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL7171239 | 0.84 | LTA4H (0.43) | LTA4HHTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL28186645 | 0.81 | ADRB1 (0.40) | LTA4HHTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL1827943 | 0.79 | LTA4H (0.40) | LTA4HCYP2C19 | |
| SCHEMBL1829382 | 0.79 | LTA4H (0.39) | LTA4HMEN1KMT2A | |
| SCHEMBL7434267 | 0.79 | HTR1A (0.50) | HTR1ASLC6A2SLC6A3SLC6A4SIGMAR1 | |
| SCHEMBL1283273 | 0.79 | ADRB1 (0.35) | LTA4HHTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL28670444 | 0.79 | TDP1 (0.39) | LTA4HHTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL28643916 | 0.77 | CYP2D6 (0.41) | LTA4HSIGMAR1HRH1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5223635 | 0.77 | LTA4H (0.38) | LTA4HMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| CN-1090480-C | Phenoxy piperazine derivatives for treating disorders of dopamine system | HOFMANN LA ROCHE AG F (CH) | 2002-09-11 | — | — | CN | disclosed |
| CN-1090480-C | Phenoxy piperazine derivatives for treating disorders of dopamine system | HOFMANN LA ROCHE AG F (CH) | 2002-09-11 | — | — | CN | disclosed |
| CN-1187128-A | Phenoxy piperazine derivatives for treating disorders of dopamine system | HOFFMANN LA ROCHE (CH) | 1998-07-08 | — | — | CN | disclosed |
| CN-1187128-A | Phenoxy piperazine derivatives for treating disorders of dopamine system | HOFFMANN LA ROCHE (CH) | 1998-07-08 | — | — | CN | disclosed |
| EP-0833639-A1 | PHENOXY PIPERAZINE DERIVATIVES FOR TREATING DISORDERS OF THE DOPAMINE SYSTEM | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-08 | — | — | EP | disclosed |
| EP-0833639-A1 | PHENOXY PIPERAZINE DERIVATIVES FOR TREATING DISORDERS OF THE DOPAMINE SYSTEM | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-08 | — | — | EP | disclosed |
| US-5614526-A | IN TREATING DISORDERS OF THE DOPAMINE SYSTEM | HOFFMANN-LA ROCHE INC. (US) | 1997-03-25 | — | — | US | disclosed |
| WO-1996041630-A1 | PHENOXY PIPERAZINE DERIVATIVES FOR TREATING DISORDERS OF THE DOPAMINE SYSTEM | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-27 | — | — | WO | disclosed |
| WO-1996041630-A1 | PHENOXY PIPERAZINE DERIVATIVES FOR TREATING DISORDERS OF THE DOPAMINE SYSTEM | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | LTA4H 1099/4885HTR1A 3377/4885SLC6A2 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.